David J. Parsley

Array ( [id] => 19379246 [patent_doc_number] => 20240269116 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => USE OF MMP INHIBITORS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME [patent_app_type] => utility [patent_app_number] => 18/568031 [patent_app_country] => US [patent_app_date] => 2022-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13144 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18568031 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18284357 [patent_doc_number] => 20230099829 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => HETEROCYCLIC PDK1 INHIBITORS FOR USE TO TREAT CANCER [patent_app_type] => utility [patent_app_number] => 17/831041 [patent_app_country] => US [patent_app_date] => 2022-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21704 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 1114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17831041 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17865480 [patent_doc_number] => 20220288215 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM [patent_app_type] => utility [patent_app_number] => 17/828640 [patent_app_country] => US [patent_app_date] => 2022-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18135 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17828640 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19343694 [patent_doc_number] => 20240252657 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => HEMTAC SMALL-MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/557959 [patent_app_country] => US [patent_app_date] => 2022-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7518 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18557959 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19989533 [patent_doc_number] => 20250127755 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-24 [patent_title] => PHARMACOLOGICAL DEPLETION OF HEME FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME [patent_app_type] => utility [patent_app_number] => 18/517049 [patent_app_country] => US [patent_app_date] => 2022-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1772 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18517049 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19800397 [patent_doc_number] => 20250066322 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => SUBSTITUTED HETEROCYCLIC COMPOUNDS [patent_app_type] => utility [patent_app_number] => 18/560520 [patent_app_country] => US [patent_app_date] => 2022-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17898 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18560520 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18050642 [patent_doc_number] => 11524008 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-13 [patent_title] => Bupropion as a modulator of drug activity [patent_app_type] => utility [patent_app_number] => 17/735470 [patent_app_country] => US [patent_app_date] => 2022-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 25 [patent_no_of_words] => 63871 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17735470 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19345152 [patent_doc_number] => 20240254115 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => New Pyridine-Sulfonamide Derivatives as Sigma Ligands [patent_app_type] => utility [patent_app_number] => 18/557933 [patent_app_country] => US [patent_app_date] => 2022-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18741 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18557933 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18003460 [patent_doc_number] => 20220362226 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING PRURITUS [patent_app_type] => utility [patent_app_number] => 17/661444 [patent_app_country] => US [patent_app_date] => 2022-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10462 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17661444 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19332472 [patent_doc_number] => 20240246902 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE [patent_app_type] => utility [patent_app_number] => 18/557760 [patent_app_country] => US [patent_app_date] => 2022-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50492 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -64 [patent_words_short_claim] => 303 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18557760 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17790328 [patent_doc_number] => 20220249419 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => C5 KETONE COMPOSITIONS, AND RELATED METHODS, FOR THERAPEUTIC AND PERFORMANCE SUPPLEMENTATION [patent_app_type] => utility [patent_app_number] => 17/732482 [patent_app_country] => US [patent_app_date] => 2022-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11011 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17732482 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17790314 [patent_doc_number] => 20220249405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION [patent_app_type] => utility [patent_app_number] => 17/730015 [patent_app_country] => US [patent_app_date] => 2022-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12246 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17730015 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19263516 [patent_doc_number] => 20240207213 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING DISORDERS WITH ORAL SYSTEMICALLY BIOAVAILABLE BUTYRATE CONJUGATES [patent_app_type] => utility [patent_app_number] => 18/556006 [patent_app_country] => US [patent_app_date] => 2022-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17244 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18556006 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19246680 [patent_doc_number] => 20240197664 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => SIRTUIN OR KLOTHO ACTIVATOR OR EXPRESSION ENHANCER, NAD+ INCREASING AGENT, AND SENOLYTIC AGENT [patent_app_type] => utility [patent_app_number] => 18/555106 [patent_app_country] => US [patent_app_date] => 2022-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6433 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18555106 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19332536 [patent_doc_number] => 20240246966 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => NEW PYRAZOLO[1,5-a] PYRIMIDINE DERIVATIVES AS SIGMA LIGANDS [patent_app_type] => utility [patent_app_number] => 18/555720 [patent_app_country] => US [patent_app_date] => 2022-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13829 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18555720 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17911271 [patent_doc_number] => 20220313666 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-06 [patent_title] => TXNIP-TRX COMPLEX INHIBITORS AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/714569 [patent_app_country] => US [patent_app_date] => 2022-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56185 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17714569 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17981111 [patent_doc_number] => 20220347147 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => COMPOSITIONS COMPRISING 15-OHEPA AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/702294 [patent_app_country] => US [patent_app_date] => 2022-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4920 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17702294 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18298471 [patent_doc_number] => 20230108157 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-06 [patent_title] => FORMULATIONS OF (S)-3-(1-(9H-PURIN-6-YLAMINO)ETHYL)-8-CHLORO-2-PHENYLISOQUINOLIN-1(2H)-ONE [patent_app_type] => utility [patent_app_number] => 17/699582 [patent_app_country] => US [patent_app_date] => 2022-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 90539 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17699582 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19318248 [patent_doc_number] => 20240239790 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor [patent_app_type] => utility [patent_app_number] => 18/279379 [patent_app_country] => US [patent_app_date] => 2022-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 93386 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18279379 [rel_patent_id] =>[rel_patent_doc_number] =>)